TREM-1 acts as an amplifier of the inflammatory response, and its pharmacological inhibition displays protective effects in various models of inflammatory disorders, in particular by dampening coagulation abnormalities and thrombocytopenia observed during acute inflammation.
Earlier initiation of anakinra (≤5 days hospitalization) was associated with reduced mortality (p=0.046), whereas thrombocytopenia (<100,000/μL) and STXBP2 mutations were both associated with increased mortality (p=0.008 and p=0.012, respectively).
Specific VEGFR-TKIs; pazopanib, regorafenib, and nintedanib were associated with a decrease risk of remaining free of an arterial thrombotic event (RR 0.96; 95%CI:0.93-0.99), thrombocytopenia (RR 0.91; 95%CI:0.89-0.93), and bleeding (RR 0.96; 95%CI:0.93-0.99) respectively.
In a multivariate model of iPAH patients (adjusted for age, sex, DLCO, PVR, creatinine and 6MW distance) thrombocytopenia was most predictive of 5-year mortality [HR 1.68 (1.32, 2.12), p < 0.0001].
The majority of patients with GD had a history of anaemia (69.6%) or thrombocytopaenia (62.0%), 40.4% had a history of bone events and 22.2% had a history of cancer.Overall, 41.2% had received ERT.
Isolated global Sphk2 deficiency was associated with thrombocytopenia, but this was not replicated by MK-restricted <i>Sphk2</i> deletion and was reversed by compound deletion of either <i>Sphk1</i> or <i>S1pr2</i>, suggesting that this phenotype arises from increased S1P export and S1P<sub>2</sub> activation secondary to redistribution of sphingosine to Sphk1.
PLAG significantly decreased plasma levels of the chemokine (C-X-C motif) ligand 1 (CXCL1), CXCL2, interleukin (IL)-6, and C-reactive protein (CRP), which were elevated consistently with the occurrence time of neutropenia, monocytopenia, and thrombocytopenia.
The analysis showed equivalent results as for conventional ADAP knockout mice: impaired thymocyte development in ADAP<sup>fl/fl</sup> Lck-Cre mice, normal NK cell and myeloid cell distribution in ADAP<sup>fl/fl</sup> NKp46-Cre mice and ADAP<sup>fl/fl</sup> LysM-Cre mice, respectively as well as thrombocytopenia in ADAP<sup>fl/fl</sup> PF4-Cre mice.
Factors independently associated with mortality were APACHE II score of the disease, patient location at sepsis diagnosis, development of acute kidney injury, and thrombocytopenia in the group of elderly patients.
The common features seen were the presence of only mild thrombocytopenia (relatively high platelet counts when assessed against the background of AML with high blast percentages), monosomy 7, myeloperoxidase positive blasts, mild eosinophilia, and poor therapeutic response.
CYP2C8*3 was significantly associated with increased risks of severe (grades 3-4) neutropenia (OR<sub>adjusted</sub> 2.11; 95% CI 1.24-3.6; dominant model) and severe thrombocytopenia (OR<sub>adjusted</sub> 4.93; 95% CI 1.69-14.35; recessive model), whereas ABCB1 variant genotypes (OR<sub>adjusted</sub> 2.13; 95% CI 1.32-3.42), in association with CYP2C8*3 wild type (GG) (OR<sub>adjusted</sub> 1.93; 95% CI 1.17-3.19), were predictive of severe fatigue.
The Perceval S bioprosthesis (LivaNova PLC, London, United Kingdom) is based on the Freedom Solo aortic bioprosthesis (LivaNova PLC), which has been reported to be associated with perioperative thrombocytopenia.
Although more of grade 3 or 4 anemia and thrombocytopenia in arm A, and higher rates grade 3 or 4 neutropenia, and leukopenia were observed in arm B. Pem-Cis first-line chemotherapy with concurrent radiation therapy for stage IV lung adenocarcinoma patients with EGFR wild-type or unknown mutation status represents a potential treatment option with acceptable toxicity and high overall survival rates.
Dnm2fl/f PF4-Cre (Dnm2<sup>Plt-/-</sup>) mice specifically lacking dynamin 2 within the platelet lineage developed severe thrombocytopenia and bleeding diathesis and Dnm2Plt platelets adhered poorly to collagen under arterial shear rates.
In addition, a lower expression level of lnc-TGS1-1 was associated with the presence of thrombocytopenia in TB patients during anti-TB treatment, and the homozygous CC genotype of rs4737420 correlated with a decreased risk of leukopenia, compared with individuals with the T allele (TT/CT genotype), in the dominant mode.
An exploratory multivariate model identified a past history of liver disease and thrombocytopenia before conditioning therapy as dominant risk factors for SOS after transplant.
Finally, we show that mice with thrombocytopenia due to the lack of heat shock protein gp96 in their megakaryocytes are protected from melanoma dissemination to the lungs.